New studies offer new promise for dry AMD patients
Assessing RPE health in your patients and identifying those most at risk will prepare you for making the right treatment recommendations as emerging therapeutics become available. At least 16 new therapies are under development to help slow or stop progression to wet AMD.
Not just for dry AMD
BluePeak blue laser autofluorescence is being used by leading clinicians to help identify many other diseases. Shown above are the characteristic BluePeak patterns for some of these diseases.
Image courtesy of Ethan Priel & the Journal of Ophthalmic Photography.
Sponsor                           Treatment


Acucela/NEI                         ACU-02
Alcon/GATE                         AL-8309B*
Alimera                                 Medidur FA
Allergan                               Brimonidine*
Alexion/COMPLETE              Eculizumab
Neurotech                            NT-501*
Ophthotech                           Dry AMD therapies
Optherion                             Early-stage AMD therapies
Othera/OMEGA                     OT-551*
Pfizer                                  RN6G
Quark/Pfizer                         PF-04523655*
Sirion                                  Fenretinide*
Oak Park Natl. Lab./TORPA   Photobiomodulation
NEI                                     Sirolimus
NEI/AREDS II                       Antioxidants
NY Eye & Ear                      Copaxone vaccinations
<   1   2   3   4   >
Macular Dystrophy
ONH Drusen
Multifocal Choroiditis
Macular Hole
Image courtesy of Frank Holz, MD
Image courtesy of William Freemean, MD
Image courtesy of Frank Holz, MD
*Phase II or III.